Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Mortality Risk Associated with Haloperidol Use Compared with Other Antipsychotics: An 11-Year Population-Based Propensity-Score-Matched Cohort Study

Abstract

Background

Haloperidol remains a frequently prescribed first-generation antipsychotic. However, haloperidol-associated mortality risk by all causes, cardiovascular disease (CVD), and pneumonia compared with other antipsychotics is unknown.

Objective

This study investigated the mortality risk associated with long-term haloperidol treatment versus that with other antipsychotics.

Methods

We identified incident antipsychotic users from 2004 to 2014 in the Clinical Data Analysis and Reporting System (CDARS), a population-based clinical database managed by the Hong Kong Hospital Authority. We included patients who were aged ≥ 18 and received antipsychotics for any indication apart from terminal illnesses or management of acute behavioural disturbance. Patients on haloperidol and other antipsychotic agents (risperidone, quetiapine, olanzapine, chlorpromazine, aripiprazole, sulpiride, amisulpride, or trifluoperazine) were matched by propensity score. Hazard ratios (HRs) for all-cause mortality and death due to CVD and pneumonia were estimated with 95% confidence intervals (CIs) using a Cox proportional hazards model.

Results

In total, 136,593 users of antipsychotics were included. During a mean follow-up of 3.2 years, the incidence of all-cause mortality ranged from 186.8/1000 person-years for haloperidol to 10.4/1000 person-years for trifluoperazine. The risk of all-cause mortality was lower with non-haloperidol antipsychotics than with haloperidol, with HRs ranging from 0.68 (95% CI 0.64–0.72 [chlorpromazine]) to 0.43 (95% CI 0.36–0.53 [trifluoperazine]). Risperidone, quetiapine, sulpiride, chlorpromazine, aripiprazole, and trifluoperazine were associated with a significantly lower risk of pneumonia-related mortality. A significantly lower risk of CVD mortality was observed for risperidone, sulpiride, chlorpromazine, and quetiapine.

Conclusion

Haloperidol was associated with increased overall mortality when compared with other antipsychotics in long-term follow-up. Treatment with haloperidol should be carefully considered, especially in older patients and patients at risk of CVD or pneumonia, since the risk of death appears to be lower with non-haloperidol agents.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Ulrichsen SP, Pedersen L, et al. Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs. Br J Clin Pharmacol. 2016;82(2):487–97.

  2. 2.

    Halfdanarson O, Zoega H, Aagaard L, Bernardo M, Brandt L, Fuste AC, et al. International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur Neuropsychopharmacol. 2017;27(10):1064–76.

  3. 3.

    Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–7.

  4. 4.

    Wang LJ, Lee SY, Yuan SS, Yang KC, Yang CJ, Lee TL, et al. Risk of mortality among patients treated with antipsychotic medications: a nationwide population-based study in taiwan. J Clin Psychopharmacol. 2016;36(1):9–17.

  5. 5.

    Lao KSJ, Tam AWY, Wong ICK, Besag FMC, Man KKC, Chui CSL, et al. Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: general and vulnerable patient groups. Pharmacoepidemiol Drug Saf. 2017;26(11):1387–94.

  6. 6.

    Roh D, Chang JG, Yoon S, Kim CH. Antipsychotic prescribing patterns in first-episode schizophrenia: a 5-year comparison. Clin Psychopharmacol Neurosci. 2015;13(3):275–82.

  7. 7.

    Marston L, Nazareth I, Petersen I, Walters K, Osborn DP. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open. 2014;4(12):e006135.

  8. 8.

    Luijendijk HJ, de Bruin NC, Hulshof TA, Koolman X. Terminal illness and the increased mortality risk of conventional antipsychotics in observational studies: a systematic review. Pharmacoepidemiol Drug Saf. 2016;25(2):113–22.

  9. 9.

    Keinanen J, Mantere O, Markkula N, Partti K, Perala J, Saarni SI, et al. Mortality in people with psychotic disorders in Finland: a population-based 13-year follow-up study. Schizophr Res. 2018;192:113–8.

  10. 10.

    Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.

  11. 11.

    Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry. 2016;173(6):600–6.

  12. 12.

    Jackson JW, VanderWeele TJ, Blacker D, Schneeweiss S. Mediators of first- versus second-generation antipsychotic-related mortality in older adults. Epidemiology. 2015;26(5):700–9.

  13. 13.

    Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–81.

  14. 14.

    Fombonne E. The prevalence of autism. JAMA. 2003;289(1):87–9.

  15. 15.

    Lao KS, Chui CS, Man KK, Lau WC, Chan EW, Wong IC. Medication safety research by observational study design. Int J Clin Pharm. 2016;38(3):676–84.

  16. 16.

    Lau WCY, Chan EW, Cheung CL, Sing CW, Man KKC, Lip GYH, et al. Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA. 2017;317(11):1151–8.

  17. 17.

    Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, et al. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ. 2017;357:j2350.

  18. 18.

    Wong AYS, Root A, Douglas IJ, Chui CSL, Chan EW, Ghebremichael-Weldeselassie Y, et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ. 2016;352:h6926.

  19. 19.

    Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149(3):586–95.

  20. 20.

    Man KK, Chan EW, Coghill D, Douglas I, Ip P, Leung LP, et al. Methylphenidate and the risk of trauma. Pediatrics. 2015;135(1):40–8.

  21. 21.

    Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107.

  22. 22.

    Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.

  23. 23.

    Hulshof TA, Zuidema SU, Ostelo RW, Luijendijk HJ. The mortality risk of conventional antipsychotics in elderly patients: a systematic review and meta-analysis of randomized placebo-controlled trials. J Am Med Dir Assoc. 2015;16(10):817–24.

  24. 24.

    Page VJ, Ely EW, Gates S, Zhao XB, Alce T, Shintani A, et al. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2013;1(7):515–23.

  25. 25.

    Girard TD, Exline MC, Carson SS, Hough CL, Rock P, Gong MN, et al. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379(26):2506–16.

  26. 26.

    Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol. 1997;120(5):968–74.

  27. 27.

    Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2–3):123–36.

  28. 28.

    De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101(1–3):295–303.

  29. 29.

    Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108(41):687–93.

  30. 30.

    Jackson JW, VanderWeele TJ, Viswanathan A, Blacker D, Schneeweiss S. The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugs. Am J Epidemiol. 2014;180(8):847–52.

  31. 31.

    Lu Y, Wang P, Zhou T, Lu J, Spatz ES, Nasir K, et al. Comparison of prevalence, awareness, treatment, and control of cardiovascular risk factors in China and the United States. J Am Heart Assoc. 2018;7(3):e007462.

  32. 32.

    Nose M, Recla E, Trifiro G, Barbui C. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2015;24(8):812–20.

  33. 33.

    Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology. 1997;37(1):75–86.

  34. 34.

    Rello J, Rodriguez R, Jubert P, Alvarez B. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Clin Infect Dis. 1996;23(4):723–8.

  35. 35.

    Nasrallah HA, Chen AT. Multiple neurotoxic effects of haloperidol resulting in neuronal death. Ann Clin Psychiatry. 2017;29(3):195–202.

  36. 36.

    Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009;70(10):1340–7.

  37. 37.

    De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics. 2005;23(Suppl 1):35–47.

  38. 38.

    Gau SS, Chung CH, Gau CS. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan. J Clin Psychopharmacol. 2008;28(3):271–8.

Download references

Acknowledgements

The authors thank the Accident and Emergency Department and the Department of Pharmacy, Queen Elizabeth Hospital (Dr. Stephen Yeung Chi Yeung, Dr. Gordon Wong, Dr. Wilson Leung, Mr. Howard Yip Ho Wah, Mr. Wong Chi Yip, Mr. Johnson Tse, Dr. Karen Chan Kin Ling), and Dr. LP Leung (Emergency Medicine Unit, The University of Hong Kong) for their contribution to the study design. We thank Ms. Lisa Lam for editing and proof-reading.

Author information

Correspondence to Esther W. Chan.

Ethics declarations

Funding

This study was supported by the General Research Fund, Research Grants Council, Hong Kong (project reference 17111615) and partially funded by the Early Career Scheme, Research Grants Council, Hong Kong (project reference 789813). The funders had no role in the design, analysis, interpretation, or publication of this study.

Conflict of interest

All authors declare that no other support has been received from any organization for the submitted work; no other financial relationships exist with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships exist or activities have been undertaken that could appear to have influenced the submitted study. KSJL was formerly employed by the University of Hong Kong, where most of the work was completed, and is currently employed by MRL, MSD China at submission. Outside the submitted work, AYSW has received Institutional Strategic Support Fund 3 Pump Priming Grant, and is currently supported by British Heart Foundation Immediate Postdoctoral Basic Science Research Fellowship. EWC has received research funding from the Wellcome Trust, UK; the National Natural Science Fund of China, China; The Hong Kong Research Grants Council, The Research Fund Secretariat of the Food and Health Bureau, the Narcotics Division of the Security Bureau of HKSAR, Hong Kong; Bristol-Myers Squibb, Pfizer, Bayer, and Janssen, a division of Johnson & Johnson, and Takeda for work unrelated to this study. ICKW has received grants from the Research Grants Council (RGC, Hong Kong), the Innovative Medicines Initiative (IMI), Shire, Janssen-Cilag, Eli-Lily, Pfizer, Bayer, and the European Union FP7 program outside the submitted work; is a member of the National Institute for Health and Care Excellence (NICE) ADHD guideline group and the British Association for Psychopharmacology ADHD guideline group; and an advisor to Shire. EYHC has completed work for Otsuka, Janssen, and DSK Biopharma. FMCB, WCC, EHML, and JEB have no conflicts of interest that are directly relevant to the content of this article.

Data Sharing

Not applicable.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 1134 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lao, K.S.J., Wong, A.Y.S., Wong, I.C.K. et al. Mortality Risk Associated with Haloperidol Use Compared with Other Antipsychotics: An 11-Year Population-Based Propensity-Score-Matched Cohort Study. CNS Drugs 34, 197–206 (2020). https://doi.org/10.1007/s40263-019-00693-5

Download citation